Research Article | Open Access
Dietary Flaxseed Oil Prevents Western-Type Diet-Induced Nonalcoholic Fatty Liver Disease in Apolipoprotein-E Knockout Mice
The prevalence of nonalcoholic fatty liver disease (NAFLD) has dramatically increased globally during recent decades. Intake of n-3 polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), is believed to be beneficial to the development of NAFLD. However, little information is available with regard to the effect of flaxseed oil rich in α-linolenic acid (ALA, C18:3n-3), a plant-derived n-3 PUFA, in improving NAFLD. This study was to gain the effect of flaxseed oil on NAFLD and further investigate the underlying mechanisms. Apolipoprotein-E knockout (apoE-KO) mice were given a normal chow diet, a western-type high-fat and high-cholesterol diet (WTD), or a WTD diet containing 10% flaxseed oil (WTD + FO) for 12 weeks. Our data showed that consumption of flaxseed oil significantly improved WTD-induced NAFLD, as well as ameliorated impaired lipid homeostasis, attenuated oxidative stress, and inhibited inflammation. These data were associated with the modification effects on expression levels of genes involved in de novo fat synthesis (SREBP-1c, ACC), triacylglycerol catabolism (PPARα, CPT1A, and ACOX1), inflammation (NF-κB, IL-6, TNF-α, and MCP-1), and oxidative stress (ROS, MDA, GSH, and SOD).
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide that is characterized by hepatocyte triacylglycerol accumulation (steatosis), which can progress to nonalcoholic steatohepatitis (NASH) or cirrhosis . During recent decades, the prevalence of NAFLD has dramatically increased globally [2–4]. In addition, NAFLD has emerged not only as a liver disease causing considerable liver-related morbidity and mortality but also as a multisystem disease that affects many extrahepatic organ systems, including the heart and the vascular system . However, at present, there are no approved pharmacological therapies for NAFLD in the clinic . Therapeutic lifestyle interventions, typically focused on nutrition and exercise, are the keys in NAFLD treatment [7, 8]. Recent research has highlighted that decreasing the intake of total fats and increasing the intake of n-3 polyunsaturated fatty acids (PUFAs) might be beneficial in the treatment of NAFLD . Delarue and Lallès gathered experimental and clinical data on the capability of long-chain n-3 PUFAs and found that eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) supplement prevented or alleviated NAFLD . The latest meta-analysis review showed beneficial changes in liver fat favored n-3 PUFA in adult NAFLD patients . Moreover, a recent study presented by Yuan et al. demonstrated that fish oil rich in DHA and EPA improved lipid metabolism in western-style diet-induced NALFD and possessed anti-inflammatory effects . Although several reports have described the preventive effects of fish oil or EPA and DHA, the n-3 PUFAs derived principally from fish oil, in experimentally induced NAFLD, there is a lack of evidence regarding the effects on NAFLD with dietary supplementation of flaxseed oil.
Flaxseed oil is a particularly rich source of α-linolenic acid (ALA, C18:3n-3), a plant-derived n-3 PUFA. Recently, flaxseed oil has been reported to ameliorate impaired lipid homeostasis with concurrent modification of proinflammatory mediators and oxidative stress, which play a key role in the development of NAFLD [13–15]. Thus, it is possible that supplementation of flaxseed oil could attenuate NAFLD. However, the impact of flaxseed oil on NAFLD has not been addressed.
The purpose of the present study was to determine the effects of dietary supplementation of flaxseed oil on NAFLD induced by western-type high-fat and high-cholesterol diet (WTD) in apolipoprotein-E knockout (apoE-KO) mice and investigate the underlying molecular mechanisms.
2. Materials and Methods
2.1. Chemical Sources
Commercial deodorized lard (food grade) was purchased from a local supermarket. The flaxseed oil (food grade) was manufactured by Caoyuankangshen Food Co. Ltd (Inner Mongolia, China). The fatty acid compositions of these experimental oils are shown in Table 1.
|ND: not detected.|
Male apoE-KO mice (4 weeks), purchased from Peking University Resources Centre (Beijing, China) with body weight of 15–19 g, were cared for according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
2.3. Experimental Procedures
The mice were acclimatized to laboratory conditions for 1 week before the experiment and randomly allocated to three groups of 12 animals each. Each group was fed one of the following three diets for 12 weeks: normal chow diet with 20.7 kcal% fat (control group), western-style lard-rich diet with 41.5% kcal fat and 1.5% cholesterol (w/w) (WTD group) , or flaxseed-oil-rich western-style diet with a total 41.5% kcal fat containing 10% flaxseed oil (w/w) and with 1.5% cholesterol (w/w) (WTD + FO group) (Table 2).
After 12 weeks, the animals were fasted for 12 h and sacrificed. Blood samples were rapidly obtained by cardiac puncture. Serum was prepared from blood centrifuged at 3000 for 10 min at 4°C. Liver tissues were frozen immediately in liquid nitrogen and stored at −80°C or fixed in 4% buffered formalin.
2.4. Histology and Morphometry Evaluations of Lipid Deposition in Liver Tissue
Lipid deposition in liver tissue was evaluated according to the method of our previous study . Fresh samples from the same position of the liver were divided into two parts. One part of samples were fixed in 4% paraformaldehyde and embedded in paraffin. Cross sections (5 μm thick) obtained from the paraffin blocks were stained with hematoxylin and eosin (H&E). The other part of samples was embedded in tissue freezing OCT medium and sectioned into consecutive 5 μm thick sections. Every sixth section was stained with Oil Red O and digitally photographed under ×200 magnification.
2.5. Measurement of Lipid Parameters in Serum and Liver
The concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in serum and liver were measured by enzymatic colorimetric assays using commercially available detection kits (BioSino Bio-Technology Co. Ltd, Beijing, China).
2.6. Detection of Reactive Oxygen Species (ROS) Levels in Liver of Mice
Fresh cross sections (5 μm) of unfixed but frozen liver were immediately incubated with 5 M dihydroethidium at 37°C for 15 min in a humidified chamber. Then, fluorescence level was visualized with a fluorescence microscope. Fluorescence intensities of the images were quantified by using the Image-Pro Plus image analysis.
2.7. Determination of Oxidative Stress Parameters in Serum and Liver
The concentration of malondialdehyde (MDA), an index of lipid peroxidation, was measured by using thiobarbituric acid colorimetry slightly modified by Ohkawa et al. . The level of glutathione (GSH) was measured according to its reaction with 5,5-dithiobis-2-nitrobenzoic acid (DTNB) into 2-nitro-5-thiobenzoic acid (TNB), following deproteinization by 5% trichloroacetic acid . The activities of superoxide dismutase (SOD) in serum and liver were measured with enzymatic colorimetric assays according to the method of Kono . The contents of MDA, GSH, and SOD in liver were standardized by protein concentration measured by the Bio-Rad Protein Assay Kit (USA).
2.8. Determination of Serum Biomarkers for Liver Injury
Serum aspartate aminotransferases (AST) and alanine aminotransferases (ALT) were measured with an enzymatic kinetic method by Mindray BS-200 automatic biochemistry analyzer (Shenzhen, China) with matching kits. Results were expressed as units per liter (U/L).
2.9. Evaluation of Inflammation Cytokines in Plasma
The levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and monocyte chemotactic protein 1 (MCP-1) in plasma were measured by enzyme-linked immunosorbent assays according to the manufacturer’s instructions of commercially available detection kits (R&D Systems, USA).
2.10. Real-Time RT-PCR Analysis
Total RNA was isolated from the stored frozen liver using the TRIzol reagent. (Invitrogen, 154 Carlsbad, CA, USA). Messenger RNA (mRNA) expression was quantified by using specific oligo primers and SYBR green-based qRT-PCR kit (TaKaRa Biotechnology Co. Ltd, Dalian, China) in the 7900HT instrument (Applied Biosystems, Foster, CA, USA). The specificity of the product was assessed from melting curve analysis. Gene expressions were determined using the 2−ΔΔCt method. The mRNA of β-actin was quantified as an endogenous control. Gene expressions are presented as fold change relative to control. Quantitative real-time RT-PCR primers are shown in Table 3.
2.11. Western Blot Analysis
Liver tissues were homogenized and lysed in RIPA Lysis Buffer (1% Triton X-100, 1% deoxycholate, and 0.1% SDS). Total protein was determined according to previously described . Tissue lysates with equal protein amounts were subjected to Western blotting. The protein was separated by 10% SDS-polyacrylamide gel and then transferred onto a PVDF membrane. The membranes were incubated with specific primary antibodies overnight at under 4°C after blocking with 5% nonfat milk solution. Then, the target proteins were incubated with the species-specific second antibodies conjugated to horseradish peroxidase. Immunoreactive bands were detected by means of an ECL plus Western Blotting Detection System (Amersham BioSciences, Little Chalfont, UK) according to the manufacturer’s instructions. Quantitative analysis of the relative density of the bands in Western blots was performed by Quantity One 4.62 software (Bio-Rad, Hercules, CA, USA). Data were corrected for background standardized to β-actin as optical density (OD/mm2). Primary antibodies were as follows: monoclonal anti-β-actin antibody (Sigma), rabbit anti-PPARα antibody (Abcam Limited), rabbit anti-CPT1A antibody (Sigma), rabbit anti-ACOX1 antibody (Abcam Limited), rabbit anti-SREBP-1c antibody (Abcam Limited), mouse anti-ACC antibody (R&D systems), rabbit antibodies against phosphorylated-p65 and p65 (Cell Signaling Technology), rabbit anti-IL-6 antibody (Cell Signaling Technology), mouse anti-TNF alpha antibody (Abcam Limited), rabbit anti-MCP-1 antibody (Abcam Limited), anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology), and anti-mouse IgG HRP-linked antibody (Cell Signaling Technology).
2.12. Statistical Analysis
Results are expressed as means ± SEM, and was considered significant. Statistical analyses of data were performed using one-way analysis of variance with SPSS 12.0 software package (SN: 59245 46841 40655 89389 09859 21671 21957 29589 12).
3.1. Effects of Flaxseed Oil on Body and Liver Weight
Treatment of flaxseed oil had no effects on body weight change compared with WTD-fed mice but significantly decreased liver weight increased by WTD (Table 4).
|Values are given as means ± SEM (). a versus the control group; b versus the WTD group.|
3.2. Effects of Flaxseed Oil on Liver Morphology
H&E and Oil Red O staining of lipid deposition in liver were analyzed to evaluate the effect of flaxseed oil on hepatic steatosis. As representative results shown in Figures 1(a) and 1(b), the mice given WTD were characterized by a large number of macrovesicular steatosis, while the circular lipid droplet was markedly reduced in the liver of mice fed with flaxseed oil. Quantitative analysis of the lipid droplet in the liver of mice (Figure 1(c)) demonstrated statistically smaller lipid droplet size in FO-treated animals than in WTD-treated mice.
3.3. Dietary Flaxseed Oil Improved Hepatic Lipid Metabolism in Mice
As shown in Figure 2, high levels of TG, TC, and LDL-C in serum and liver induced by WTD were significantly reduced after exposure to flaxseed oil. However, flaxseed oil intervention had no effect on serum HDL-C.
To investigate the underlying molecular mechanism by which dietary flaxseed oil modulates lipid metabolism, gene and protein expressions of the major factors involved in hepatic fatty acid catabolism and synthesis were detected. Results showed that flaxseed oil supplement apparently reversed the decreased mRNA and protein expressions of hepatic peroxisome proliferator-activated receptor alpha (PPARα), carnitine palmitoyltransferase 1A (CPT1A), and acyl CoA oxidase 1 (ACOX1) induced by WTD (Figure 3). In addition, it was also observed that administrations of flaxseed oil significantly downregulated the mRNA and protein expressions of sterol regulatory element binding protein-1c (SREBP-1c) and acetyl-CoA carboxylase (ACC) (Figure 4).
3.4. Dietary Flaxseed Oil Inhibited Oxidative Stress
In this experiment, in situ ROS production of liver was determined. As illustrated in Figures 5(a) and 5(b), high level of ROS in liver induced by WTD was significantly reduced after exposure to flaxseed oil. Moreover, flaxseed oil consumption apparently decreased the concentrations of MDA and elevated the levels of GSH and SOD in serum and liver (Figures 6(a), 6(b), 6(c), 6(d), 6(e), and 6(f)).
3.5. Intervention with Flaxseed Oil Decreased Hepatic Transaminase Activities
Plasma AST and ALT levels are important liver injury markers. Compared with the control group, the AST and ALT levels in mice fed WTD were significantly increased, whereas compared with the WTD group, the activity of AST and ALT in the WTD + FO group decreased by 22.4% () and 18.7% (), respectively (Figures 7(a) and 7(b)).
3.6. Application of Flaxseed Oil Alleviated Inflammation in Mice
As illustrated in Figure 8, compared with control, mice fed on WTD exhibited significantly higher plasma levels of IL-6, TNF-α, and MCP-1. A significant reduction of IL-6, TNF-α, and MCP-1 was noted after flaxseed oil treatment. In an effort to seek an explanation for the inflammation induced by WTD and the protection effect exerted by flaxseed oil on this process, at the molecular level, we assessed the expression of nuclear factor-kappa B (NF-κB), a crucial regulator of inflammation cytokines involved in NAFLD. The data clearly displayed that flaxseed oil-feeding mice had lower protein levels of phospho-p65, a transcriptionally active form of NF-κB, compared with the mice given WTD (Figures 9(a) and 9(b)). In company with these results, the increased mRNA and protein expressions of NF-κB target genes IL-6, TNF-α, and MCP-1 induced by WTD in liver were dramatically reversed by flaxseed oil intervention (Figures 10(a), 10(b), 10(c), 10(d), 10(e), and 10(f)).
NAFLD is a burgeoning public health concern worldwide because of its high morbidity and its association with cardiovascular diseases and type 2 diabetes [22, 23]. In recent years, pathogenesis and treatment of NAFLD are attracting greater attention. A growing body of evidence emphasizes that increased serum levels of lipids as a result of WTD can cause fat accumulation, oxidative stress, and inflammation in the liver, which leads to NAFLD . To simulate the pathogenesis of NAFLD as closely as possible to the human condition, we created a mouse model where NAFLD, lipid disorder, oxidative stress, and inflammation were induced by WTD in apoE-KO mice. This study provides the first evidence, to our knowledge, of dietary flaxseed oil-improved NAFLD induced by WTD via restoring impaired lipid metabolism, attenuating oxidative stress, and inhibiting inflammation.
Anomalous lipid metabolism plays a crucial role in the progression of NAFLD, attacking hepatocytes . The latest study setup by Wang et al. demonstrated that dietary ALA-rich flaxseed oil prevented alcoholic hepatic steatosis via ameliorating lipid homeostasis at the adipose tissue-liver axis in mice . Meanwhile, it has been well established that increased consumption of ALA was associated with improvements in the level of TG and gene expression involved in fatty acid metabolism [27, 28]. Consistent with previous research, in this work, we found that intervention of flaxseed oil decreased TG and TC in serum and liver, which indicated that supplement of flaxseed oil offered a strategy for optimizing lipid levels. To better explain the effects of flaxseed oil on the lipid, we further assayed mRNA and protein expressions of the factors in charge of hepatic lipid metabolism.
Excessive accumulation of TG in hepatocytes, as a precursor for NAFLD, is mainly composed of upregulated de novo fat synthesis and impaired fatty acid β-oxidation . De novo fat synthesis in the liver converts excess carbohydrates into fatty acids and their esterified TG forms through the activity of many enzymes, including ACC, fatty acid synthase (FAS), and stearoyl-CoA desaturase 1 (SCD1). These lipogenic gene expressions can be regulated by a key transcriptional factor, SREBP-1c . Devarshi et al. demonstrated that flaxseed oil diet improved lipid metabolism through downregulating SREBP-1c in diabetic rats . Our study showed similar data with previous reports that flaxseed oil intervention decreased mRNA and protein expressions of SREBP-1c and ACC in liver. These results indicate that flaxseed oil supplementation may inhibit the SREBP-1c pathway to downregulate ACC expression, which in turn reduces TG synthesis.
On the other hand, it has been considered that n-3 PUFA exhibited TG-reducing effects through regulation of PPARα, which controls hepatic fatty acid catabolism [32, 33]. PPARα, which belongs to the super family of ligand activated nuclear hormone receptors, is thought to be the principal regulator in the fatty acid β-oxidation through modulation of CPT1A and ACOX1, the rate-limiting enzymes in mitochondrial and peroxisomal fatty acid oxidation, respectively . In a previous study, flaxseed oil diet was observed to improve lipid metabolism through upregulating PPARα in diabetic rats . Recently, Rincón-Cervera et al. demonstrated that a larger supply of ALA modulated the fatty acid metabolism through increasing the expression and DNA-binding of PPARα . As we expected, in this work, administration of flaxseed oil upregulated mRNA and protein expressions of hepatic PPARα, as well as its target genes CPT1A and ACOX1. This data made us speculate that increased β-oxidation of fatty acids might be responsible for the TG-lowering effect of flaxseed oil displayed in this study. Since the activations of PPARα and SREBP-1c have been shown to stimulate fatty acid β-oxidation and TG synthesis, respectively, we believe that increased β-oxidation of fatty acid and reduced TG synthesis are likely responsible for the TG-lowering effect of flaxseed oil. Based on the important lipid modulation role of molecules mentioned above and the results in the present study, we suggest that improvement effects of flaxseed oil on lipid profiles and NAFLD may be linked to the regulation of SREBP-1c and PPARα.
According to the classical “two-hit” hypothesis and modified “multiple-hit” hypothesis of NAFLD pathogenesis, oxidative stress is important in mediating the progression of NAFLD from steatosis to NASH, fibrosis, and cirrhosis . An established source of oxidative stress is ROS generated by the free fatty acid metabolism in microsomes, peroxisomes, and mitochondria. ROS attack PUFA and initiate lipid peroxidation within cells, resulting in the formation of aldehyde by-products, such as MDA, which could activate the inflammatory response and, consequently, cause liver stellate cell fibrogenesis . Recently, reports showed that dietary flaxseed oil was able to ameliorate renal oxidative stress in streptozotocin-nicotinamide-induced diabetic rats and modulate gamma irradiation and carbon tetrachloride-induced oxidative stress in the brain of female rats, which indicated that flaxseed oil treatment had an antioxidative function [38, 39]. In the present study, ROS production and the lipid peroxidation indicator MDA were increased in both serum and liver tissue in WDT-fed mice, whereas the levels of GSH and SOD, two potent antioxidants, were decreased in both serum and liver tissue. However, a pronounced reduction of ROS along with lower concentration of MDA and higher levels of GSH and SOD were observed in FO-fed animals than in mice on WTD. These results suggested that the potential effect of flaxseed oil in preventing oxidative stress could be due to the ability to reduce free radical production or through increased free radical scavenging activity. Antioxidant potential of flaxseed oil may represent another mechanism for alleviating and improving NAFLD.
Besides oxidative stress, inflammation is believed to be a substantial contribution that mediates “second-hits” to steatotic livers and exacerbates liver injury . In the advanced stage of NAFLD, excessive fat acid accumulation in hepatocytes resulting from dysregulation of the lipid metabolism and oxidative stress will further activate inflammatory responses, which ultimately causes hepatic injury and fibrosis . Consistent with this pathological progression of NAFLD/NASH, a growing body of evidence showed that the patients with NAFLD/NASH have elevated concentrations of IL-6, TNF-α, and MCP-1 [42, 43]. A recent study showed that dietary flaxseed oil ameliorated inflammation in streptozotocin-nicotinamide-induced diabetic rats . In addition, Hendawi et al. demonstrated that flaxseed oil was able to protect against thiacloprid-induced hepatotoxicity . Here, we found higher levels of IL-6, TNF-α, and MCP-1 accompanying elevated levels of AST and ALT in the WTD group than in the control, which indicated ongoing NASH and liver injury, while dietary flaxseed oil significantly reduced plasma levels of IL-6, TNF-α, and MCP-1 initially increased by WTD. Since these inflammatory markers have a key role in mediating inflammation, the positive impact of dietary flaxseed oil on IL-6, TNF-α, and MCP-1 in plasma observed in this research supported that beneficial function in NAFLD prevention of flaxseed oil is at least partly through perfecting inflammatory response. In order to investigate the reason for inflammation induced by WTD and the protection effect exerted by flaxseed oil on this process, at the molecular level, we assessed the expression of nuclear factor-kappa B (NF-κB). NF-κB is a nuclear protein factor that participates in the regulation of a variety of protein genes and causes disease through the induction of cytokines, which are related to immunity, inflammation, and fibrosis . Several studies have found that the activation of NF-κB could facilitate the occurrence and development of NAFLD, and the underlying mechanisms are related to inflammation and oxidative stress [46–48]. In addition, it has been published that NASH patients and rodent models of NASH had greater NF-κB activation and protein expressions of NF-κB-dependent proinflammatory genes including TNF-α and MCP-1 [49, 50]. Lately, an in vitro experiment conducted by Monk et al. showed that flaxseed oil cocultures reduced activation of inflammatory transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cell) p65 in CD8(+) T cell . This is corroborated in our study by flaxseed oil-mediated decrease in protein expression of phospho-p65, a transcriptionally active form of NF-κB. The lower activity of NF-κB and decreased mRNA and protein expressions of NF-κB target genes IL-6, TNF-α, and MCP-1 in liver observed in the WTD + FO group indicate that the inhibition effect of flaxseed oil on inflammation may through regulating NF-κB. In addition, since NF-κB can be activated in a redox-dependent manner , we suggest that NF-κB activation increase may be a result of oxidative stress induced by WTD and leads to inflammation which contributes to hepatic injury. Accordingly, the inhibition effect of flaxseed oil on NF-κB described in this study may be also associated with its antioxidant activity.
The present study demonstrated that chronic WTD intake induced NAFLD. Dietary flaxseed oil compensated for WTD-induced lipid metabolism disorder, depressed hepatic oxidative stress, and inflammation, which contribute to the amelioration of NAFLD progress. The results suggest that flaxseed oil may be a potential dietary therapeutic tool against NAFLD.
Conflicts of Interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
This work was supported by the National Natural Science Foundation of China (81602856), Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi (2016154), and Startup Foundation for Doctors of Shanxi Medical University (03201518).
- M. Ahmed, “Non-alcoholic fatty liver disease in 2015,” World Journal of Hepatology, vol. 7, no. 11, pp. 1450–1459, 2015.
- M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994,” American Journal of Epidemiology, vol. 178, no. 1, pp. 38–45, 2013.
- V. W. Wong, “Nonalcoholic fatty liver disease in Asia: a story of growth,” Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 18–23, 2013.
- B. Amirkalali, H. Poustchi, H. Keyvani et al., “Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran,” Iranian Journal of Public Health, vol. 43, no. 9, pp. 1275–1283, 2014.
- A. K. Panda, R. Avasthi, and G. Nath, “The association of cardiovascular risk factors and prevalence of MetS in non-alcoholic fatty liver disease (NAFLD),” Journal of the Association of Physicians of India, vol. 64, no. 1, p. 48, 2016.
- J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011.
- A. Eshraghian, “High prevalence of nonalcoholic fatty liver disease in the middle east: lifestyle and dietary habits,” Hepatology, vol. 65, no. 3, p. 1077, 2016.
- E. Rusu, G. Enache, M. Jinga et al., “Medical nutrition therapy in non-alcoholic fatty liver disease--a review of literature,” Journal of Medicine and Life, vol. 8, no. 3, pp. 258–262, 2015.
- K. Nakamoto, T. Obata, A. Hirasawa, K. I. Kim, S. R. Kim, and S. Tokuyama, “A future perspective on the involvement of n-3 polyunsaturated fatty acid in the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis,” Yakugaku Zasshi, vol. 136, no. 4, pp. 583–589, 2016.
- J. Delarue and J. P. Lallès, “Nonalcoholic fatty liver disease: roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA,” Molecular Nutrition & Food Research, vol. 60, no. 1, pp. 147–159, 2016.
- W. Lu, S. Li, J. Li et al., “Effects of omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis,” Gasteroenterology Research and Practice, vol. 2016, Article ID 1459790, 11 pages, 2016.
- F. Yuan, H. Wang, Y. Tian et al., “Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study,” Lipids in Health and Disease, vol. 15, p. 20, 2016.
- J. Xu, H. Gao, L. Song et al., “Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard,” Lipids in Health and Disease, vol. 12, no. 1, p. 58, 2013.
- X. Zhang, H. Wang, P. Yin, H. Fan, L. Sun, and Y. Liu, “Flaxseed oil ameliorates alcoholic liver disease via anti-inflammation and modulating gut microbiota in mice,” Lipids in Health and Disease, vol. 16, no. 1, p. 44, 2017.
- J. Xu, S. Rong, H. Gao et al., “A combination of flaxseed oil and astaxanthin improves hepatic lipid accumulation and reduces oxidative stress in high fat-diet fed rats,” Nutrients, vol. 9, no. 3, p. 271, 2017.
- Y. Nakashima, A. S. Plump, E. W. Raines, J. L. Breslow, and R. Ross, “ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree,” Arteriosclerosis Thrombosis and Vascular Biology, vol. 14, no. 1, pp. 133–140, 1994.
- H. Han, W. Cui, L. Wang et al., “Lutein prevents high fat diet-induced atherosclerosis in ApoE-deficient mice by inhibiting NADPH oxidase and increasing PPAR expression,” Lipids, vol. 50, no. 3, pp. 261–273, 2015.
- H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979.
- J. J. Eady, T. Orta, M. F. Dennis, M. R. Stratford, and J. H. Peacock, “Glutathione determination by the Tietze enzymatic recycling assay and its relationship to cellular radiation response,” British Journal of Cancer, vol. 72, no. 5, pp. 1089–1095, 1995.
- Y. Kono, “Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase,” Archives of Biochemistry and Biophysics, vol. 186, no. 5, pp. 189–195, 1978.
- E. F. Hartree, “Determination of protein: a modification of the Lowry method that gives a linear photometric response,” Analytical Biochemistry, vol. 48, no. 2, pp. 422–427, 1972.
- N. Motamed, B. Rabiee, H. Poustchi et al., “Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases,” Clinical Gastroenterology and Hepatology, vol. 41, no. 1, pp. 31–38, 2016.
- F. Bril and K. Cusi, “Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus,” Endocrinology and Metabolism Clinics of North America, vol. 45, no. 4, pp. 765–781, 2016.
- R. M. Carr, A. Oranu, and V. Khungar, “Nonalcoholic fatty liver disease: pathophysiology and management,” Gastroenterology Clinics of North America, vol. 45, no. 4, pp. 639–652, 2016.
- G. Musso, R. Gambino, and M. Cassader, “Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD),” Progress in Lipid Research, vol. 48, no. 1, pp. 1–26, 2009.
- M. Wang, X. J. Zhang, K. Feng et al., “Dietary α-linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis via ameliorating lipid homeostasis at adipose tissue-liver axis in mice,” Scientific Reports, vol. 6, article 26826, 2016.
- H. Han, P. Yan, L. Chen et al., “Flaxseed oil containing α-linolenic acid ester of plant sterol improved atherosclerosis in apoE deficient mice,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 958217, 17 pages, 2015.
- A. De Tonnac, E. Labussière, A. Vincent, and J. Mourot, “Effect of α-linolenic acid and DHA intake on lipogenesis and gene expression involved in fatty acid metabolism in growing-finishing pigs,” British Journal of Nutrition, vol. 116, no. 1, pp. 7–18, 2016.
- Y. Kawano and D. E. Cohen, “Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease,” Journal of Gastroenterology, vol. 48, no. 4, pp. 434–441, 2013.
- S. Qin, J. Yin, and K. Huang, “Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPARα and SREBP-1c in L-02 cells,” Lipids, vol. 51, no. 7, pp. 797–805, 2016.
- P. P. Devarshi, N. M. Jangale, A. E. Ghule, S. L. Bodhankar, and A. M. Harsulkar, “Beneficial effects of flaxseed oil and fish oil diet are through modulation of different hepatic genes involved in lipid metabolism in streptozotocin-nicotinamide induced diabetic rats,” Genes & Nutrition, vol. 8, no. 3, pp. 329–342, 2013.
- J. Su, C. Ma, C. Liu, C. Gao, R. Nie, and H. Wang, “Hypolipidemic activity of peony seed oil rich in α-linolenic, is mediated through inhibition of lipogenesis and upregulation of fatty acid β-oxidation,” Journal of Food Science, vol. 81, no. 4, pp. 1001–1009, 2016.
- N. Tanaka, X. Zhang, E. Sugiyama et al., “Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice,” Biochemical Pharmacology, vol. 80, no. 10, pp. 1601–1612, 2010.
- G. A. Preidis, K. H. Kim, and D. D. Moore, “Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance,” Journal of Clinical Investigation, vol. 127, no. 4, pp. 1193–1201, 2017.
- M. Á. Rincón-Cervera, R. Valenzuela, M. C. Hernandez-Rodas et al., “Vegetable oils rich in alpha linolenic acid increment hepatic n-3 LCPUFA, modulating the fatty acid metabolism and antioxidant response in rats,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, vol. 111, pp. 25–35, 2016.
- S. Petta, A. Gastaldelli, E. Rebelos et al., “Pathophysiology of non alcoholic fatty liver disease,” International Journal of Molecular Sciences, vol. 17, no. 12, article E2082, 2016.
- V. Maillet, V. Paradis, D. Couton et al., “Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 125, no. 3, pp. 981–992, 2015.
- N. M. Jangale, P. P. Devarshi, S. B. Bansode, M. J. Kulkarni, and A. M. Harsulkar, “Dietary flaxseed oil and fish oil ameliorates renal oxidative stress, protein glycation, and inflammation in streptozotocin-nicotinamide-induced diabetic rats,” Journal of Physiology and Biochemistry, vol. 72, no. 2, pp. 327–336, 2016.
- A. F. Ismail, A. A. Salem, and M. M. Eassawy, “Modulation of gamma-irradiation and carbon tetrachloride induced oxidative stress in the brain of female rats by flaxseed oil,” Journal of Photochemistry and Photobiology B, vol. 161, pp. 91–99, 2016.
- M. Sakamoto, H. Tsujikawa, K. Effendi et al., “Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease,” Pathology International, vol. 67, no. 1, pp. 1–7, 2017.
- M.Y. Kim, “The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease,” The Korean Journal of Gastroenterology, vol. 69, no. 6, pp. 341–347, 2017.
- V. Ajmera, E. R. Perito, N. M. Bass et al., “Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease,” Hepatology, vol. 65, no. 1, pp. 65–77, 2017.
- S. A. Polyzos, J. Kountouras, V. Polymerou, K. G. Papadimitriou, C. Zavos, and P. Katsinelos, “Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease,” Annals of Hepatology, vol. 15, no. 5, pp. 705–714, 2016.
- M. Y. Hendawi, R. T. Alam, and S. A. Abdellatief, “Ameliorative effect of flaxseed oil against thiacloprid-induced toxicity in rats: hematological, biochemical, and histopathological study,” Environmental Science and Pollution Research International, vol. 23, no. 12, pp. 11855–11863, 2016.
- S. C. Sun, “The non-canonical NF-κB pathway in immunity and inflammation,” Nature Reviews Immunology, 2017.
- D. Y. Tan, H. Y. Shi, C. P. Li, X. L. Zhong, and M. Kang, “Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 21, no. 19, pp. 5877–5883, 2015.
- L. Li, J. Hai, Z. Li et al., “Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease,” Food and Chemical Toxicology, vol. 63, pp. 166–173, 2014.
- L. Wu and Y. Xie, “Effect of NF-κB on the pathogenic course of non-alcoholic fatty liver disease,” Zhong Nan Da Xue Xue Bao. Yi Xue Ban, vol. 42, no. 4, pp. 463–467, 2017.
- L. A. Videla, G. Tapia, R. Rodrigo et al., “Liver NF-κB and AP-1 DNA binding in obese patients,” Obesity, vol. 17, no. 5, pp. 973–979, 2009.
- A. Dela Pena, I. Leclercq, J. Field, J. George, B. Jones, and G. Farrell, “NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis,” Gastroenterology, vol. 129, no. 5, pp. 1663–1674, 2005.
- J. M. Monk, D. M. Liddle, M. J. Brown et al., “Anti-inflammatory and anti-chemotactic effects of dietary flaxseed oil on CD8+ T cell/adipocyte-mediated cross-talk,” Molecular Nutrition & Food Research, vol. 60, no. 3, pp. 621–630, 2016.
- H. J. Park, J. Y. Lee, M. Y. Chung et al., “Green tea extract suppresses NFκB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis,” Journal of Nutrition, vol. 142, no. 1, pp. 57–63, 2012.
Copyright © 2017 Hao Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.